AstraZeneca PLC (AZN) News & EventsAZNAstraZeneca PLC

AstraZeneca and Amgen's Tezspire Trial Results Show Significant Improvements

Full results from the "positive" Phase 3 CROSSING trial showed that AstraZeneca (AZN) and Amgen's (AMGN) Tezspire demonstrated statistically significant and clinically meaningful improvements in the co-primary endpoints of histologic remission and the frequency and severity of dysphagia in adolescent and adult patients with symptomatic and uncontrolled eosinophilic esophagitis, despite continued treatment with background medications. These improvements were observed at week 24 in both doses tested compared to placebo. Efficacy was sustained in both doses through week 52, as measured in key secondary endpoints. Results from the CROSSING trial were presented in a late-breaking oral presentation at United European Gastroenterology Week 2026 in Barcelona, Spain. Treatment with Tezspire, administered subcutaneously every four weeks, achieved histologic remission for 64.8% for the 210mg dose and 68.9% for the 420mg dose of patients at week 24, compared to 3.5% of patients on placebo. Tezspire also reduced the frequency and severity of dysphagia symptoms by 18.8 points for the 210mg dose and 22.0 points for the 420mg dose from baseline vs. 14.7 points on placebo, as measured by the Dysphagia Symptom Questionnaire score, a patient-reported outcome measure. These results were sustained through week 52, assessed in key secondary endpoints: 67.8% (210mg dose) and 63.3% (420mg dose) of patients taking Tezspire achieved histologic remission vs. 5.4% on placebo and there was continued symptom improvement through week 52, with patients taking Tezspire achieving an average reduction from baseline of 22.1 points (210mg dose) and 24.0 points (420mg dose) in the DSQ score vs. 13.2 points on placebo.

AstraZeneca and Amgen's TEZSPIRE Shows Significant Improvement in EoE Symptoms

Full results from the Phase III CROSSING trial showed that AstraZeneca (AZN) and Amgen's (AMGN) TEZSPIRE demonstrated statistically significant and clinically meaningful improvements in the co-primary endpoints of histologic remission and the frequency and severity of dysphagia in adolescent and adult patients with symptomatic and uncontrolled eosinophilic esophagitis, EoE, despite continued treatment with background medications. These improvements were observed at week 24 in both doses tested compared to placebo. Efficacy was sustained in both doses through week 52, as measured in key secondary endpoints.

Oracle Partners with AstraZeneca for AI Collaboration

Oracle (ORCL) announced an agreement with AstraZeneca (AZN) to explore how AI and real-world data can help clinicians identify eligible patients for clinical trials, accelerate evidence generation, and bring relevant research insights into everyday care. The collaboration is expected to combine AstraZeneca's scientific and therapeutic expertise with Oracle's health data, cloud, AI, analytics, and clinical workflow capabilities. Through a non-binding agreement, the companies plan to explore selected use cases that could improve clinical-trial efficiency and success by leveraging modern applications and AI to help care teams identify eligible patients earlier and easier, resulting in greater access to clinical trials for patients in need and helping to overcome one of the largest obstacles in clinical trials - patient recruitment. Initial disease areas to be explored could include oncology; cardiovascular, renal and metabolic diseases; respiratory and immunology; and rare diseases. AstraZeneca and Oracle intend to explore a continuous learning model in which insights from clinical research and routine care help inform future study design, safety monitoring, and patient care. The companies plan to establish shared governance, reusable technical components, and agreed outcome measures to assess results and determine whether successful approaches could extend across disease areas and geographies.